Clinical trialPhase 2Not yet recruiting
Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer
A Prospective, Exploratory Study of Retlirafusp Alfa Combined With Famitinib and AG-Chemotherapy as First-Line Therapy for Unresectable Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 31 August 2026
- Expected end
- 31 August 2029
- Enrollment
- 88 participants
- Sites
- 1
- Primary outcomes
- Progression-Free Survival
- Sponsor
- Other
- Results posted
- No
- Last update
- 11 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try